News | November 08, 2024
Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
